Post-Acute Withdrawal Syndrome: Long Antidepressant Withdrawal Explained

Post-Acute Withdrawal Syndrome: What the Evidence Shows About Long Antidepressant Withdrawal

Most patients hear that antidepressant withdrawal lasts a week or two. For many, that’s true. A smaller group stops an SSRI or SNRI, gets through the first rough fortnight, then keeps feeling off for months. Dizzy spells. A restless anxiety that doesn’t match the depression they started treatment for.

That longer course has a name borrowed from addiction medicine: post-acute withdrawal syndrome, often shortened to PAWS.

I’m Dr. Baghel, a board-certified psychiatrist practicing in North Carolina. I’m board-certified by the American Board of Psychiatry and Neurology in psychiatry and forensic psychiatry. This piece is educational. There’s no proven cure for the persistent form of antidepressant withdrawal, and saying otherwise would mislead the people most affected by it. What the evidence does support is a clearer picture of who gets stuck and how to tell protracted withdrawal apart from a returning illness.

What Post-Acute Withdrawal Syndrome Means

The term comes from substance-use medicine. The SAMHSA advisory on protracted withdrawal describes two phases: an acute phase that passes in days to weeks, and a protracted phase, where symptoms linger past that window or surface again after it. Clinicians have called the protracted phase post-acute withdrawal, chronic withdrawal, or extended withdrawal. The classic settings are alcohol, opioids, and benzodiazepines.

Antidepressants weren’t part of that original conversation. They are now. The same logic applies. There’s a defined acute withdrawal, and for a subset of people, a longer tail that doesn’t resolve on the textbook schedule.

For SSRIs and SNRIs, that tail has its own clinical name. Guy and Virginie-Anne Chouinard called it persistent post-withdrawal disorder, and the framework sits inside antidepressant discontinuation syndrome more broadly.

The Three-Syndrome Framework for Antidepressant Withdrawal

Chouinard’s 2015 classification, later expanded into a broader review by Cosci and Chouinard in 2020, splits what happens after a dose drop into three distinct pictures.

New withdrawal symptoms are physical and psychological symptoms the person didn’t have before treatment. Dizziness, electric-shock sensations (often called brain zaps), nausea, insomnia, irritability. They appear within days and usually fade within weeks.

Rebound is the original anxiety or depression returning briefly, more intensely than before, then settling back down.

Persistent post-withdrawal disorder is the one that matters here. Symptoms continue beyond roughly six weeks after stopping, sometimes for months. They can include the new withdrawal symptoms above plus a shifted, unfamiliar emotional state. By Chouinard’s criteria, this is a withdrawal phenomenon in its own right, separate from a relapse of the underlying condition.

How Common Is Protracted Withdrawal, Really?

The honest answer is that nobody has a clean number, and the estimates fight each other.

On one end, a 2019 systematic review by Davies and Read found that about 56% of people reported withdrawal symptoms, and nearly half of those rated them severe. Critics pointed out that much of that data came from online surveys of people who had already sought out withdrawal support, which skews toward worse experiences.

On the other end, a 2024 Lancet Psychiatry meta-analysis by Henssler and colleagues pooled 79 studies and more than 21,000 patients. About one in three reported symptoms after stopping, but once placebo discontinuation was subtracted, the drug-attributable rate fell to roughly one in six or seven. Severe symptoms showed up in 2.8% of people stopping an antidepressant, against 0.6% of people stopping placebo.

So the average person stopping an antidepressant does fine or has a brief, manageable course. A minority does not. The persistent tail is real, and the people in it are easy to overlook because most of their peers recover quickly.

Withdrawal or Relapse? Telling Them Apart

This is the question that decides everything. The two get managed in opposite directions, so getting it wrong has a real cost. People land back on a drug they didn’t need, or push through something a small dose could have eased.

Timing is the first clue. Withdrawal tends to start fast, within days of a dose cut or a missed dose. Relapse builds slowly over weeks, as the original mood or anxiety syndrome reassembles itself.

Symptom character is the second. Withdrawal brings physical and neurological symptoms that weren’t part of the original illness: dizziness, brain zaps, balance problems, nausea, a flu-like feeling. A depression relapse looks like the depression did before.

Response to reinstatement is the most useful signal of all. Withdrawal symptoms usually ease within hours to days of restarting the antidepressant, even at a fraction of the prior dose. A true relapse does not lift that quickly. Horowitz and Taylor list this quick response to restarting the drug among the features that separate withdrawal from relapse, and Chouinard and Chouinard built the same test into their 2015 classification. That’s why a careful history beats a guess.

Risk also tracks with the drug. Short-half-life agents clear fast, so they punish missed doses and abrupt stops hardest. That’s the story behind venlafaxine withdrawal and the difficulty many people have coming off paroxetine. At the other end, fluoxetine’s long half-life means it tapers itself, and a protracted course after it is uncommon.

Duloxetine sits on the harder end of that range. My guide to Cymbalta withdrawal covers its acute phase and the capsule problem that complicates tapering.

If you’re not sure whether you’re dealing with withdrawal or a returning illness, that’s the exact question a psychiatric evaluation is built to answer. You can book an evaluation to work through it.

Why Some People Get Stuck: The Mechanism

Antidepressants change the brain they act on. After months or years of SSRI or SNRI exposure, serotonin signaling adapts. Receptor sensitivity shifts, and the system recalibrates around the drug being present. Take the drug away and the brain has to readapt. For most people that happens fast enough. For some it doesn’t.

The dosing math makes the last stretch the hardest. Serotonin transporter occupancy doesn’t fall in a straight line as the dose drops. Horowitz and Taylor showed it follows a hyperbolic curve, so the final few milligrams hold a disproportionate share of receptor occupancy. Going from 5 mg to zero can cut occupancy more than going from 40 mg to 20. That’s why abrupt stops and fast tapers at low doses provoke symptoms out of proportion to the size of the dose change.

I plan slow tapers by video for adults across North Carolina, and my page on psychiatrist-guided tapering explains how I supervise them.

Why a subset slides into a persistent course is not settled. The leading idea is that neuroadaptation reverses slowly or incompletely in vulnerable people.

What the Workup Looks Like

When symptoms drag on, the first job is to rule out everything else before calling it protracted withdrawal. Thyroid disease, anemia, and vitamin deficiencies can all mimic the fatigue, fog, and low mood people report. So can a genuine relapse of the original condition. Skipping those steps can lead to the wrong diagnosis.

Reinstatement plays two roles. A return of symptoms that eases quickly after restarting a small dose supports withdrawal over relapse, and it gives the person relief while a slower taper is planned. Horowitz and Taylor’s hyperbolic approach, and the staged reduction NICE now recommends, both lean on this logic. The earlier Fava systematic review had already documented that late-onset and longer-lasting courses happen even with gradual tapering.

What the evidence does not support is a cure for the persistent form. No medication, supplement, or protocol has been shown in controlled trials to reliably resolve protracted antidepressant withdrawal. Anyone selling one is ahead of the data. Good care means naming that uncertainty and supporting the person through a timeline that’s often measured in months.

The patient community deserves credit for documenting protracted withdrawal. A 2021 paper in Therapeutic Advances in Psychopharmacology, written by patient advocate Adele Framer, drew on peer-support communities that had been recording these courses for years.

Some persistent symptoms are syndromes of their own. Post-SSRI sexual dysfunction is the clearest example, sexual side effects that continue after the drug is gone. And because protracted withdrawal can look like generalized anxiety, an accurate diagnosis is what keeps the treatment honest.

Frequently Asked Questions

How long can post-acute withdrawal syndrome last?

Most antidepressant withdrawal resolves within a few weeks. The persistent form, by Chouinard’s definition, runs beyond about six weeks and can last several months. Reliable data on the longest courses is thin, which is part of why the syndrome is under-recognized.

Is PAWS the same as relapse?

No. Relapse is the return of the original depression or anxiety, building gradually over weeks. Post-acute withdrawal syndrome brings physical symptoms like dizziness and brain zaps that weren’t part of the original illness, starts faster, and often eases when a small dose of the antidepressant is reinstated.

Does everyone who stops an antidepressant get PAWS?

No. Most people stop without a prolonged course. Estimates of who has any withdrawal range widely, from roughly one in six in placebo-adjusted analyses to about half in survey-based reviews. The protracted, persistent tail is a minority within that group.

Can protracted antidepressant withdrawal be cured?

There’s no proven cure for the persistent form. No drug or supplement has held up in controlled trials. Management focuses on a slow, individualized taper, reinstatement when symptoms are severe, and support over time.

Which antidepressants are most likely to cause it?

Short-half-life agents such as venlafaxine and paroxetine carry the highest risk. Fluoxetine, with its long half-life, carries the lowest and is sometimes used to bridge a difficult taper.

Sertraline is not on the high-risk lists, which is covered in Zoloft withdrawal.

Henssler’s 2024 analysis placed escitalopram among the drugs with more frequent discontinuation symptoms. My guide to Lexapro withdrawal covers how I taper it.

Henssler’s 2024 analysis also placed desvenlafaxine among the drugs with more frequent discontinuation symptoms. My guide to Pristiq withdrawal covers how I taper desvenlafaxine.

This article is for educational purposes only and is not medical advice. It does not create a physician-patient relationship. Do not stop or change an antidepressant on your own; abrupt discontinuation can be harmful. Talk with a qualified clinician about any changes to your medication.

References

1. Cosci F, Chouinard G. Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. Psychother Psychosom. 2020;89(5):283-306. PMID: 32259826.
2. Chouinard G, Chouinard VA. New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal. Psychother Psychosom. 2015;84(2):63-71. PMID: 25721565.
3. Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addict Behav. 2019;97:111-121. PMID: 30292574.
4. Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024;11(7):526-535. PMID: 38851198.
5. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6(6):538-546. PMID: 30850328.
6. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychother Psychosom. 2015;84(2):72-81. PMID: 25721705.
7. Substance Abuse and Mental Health Services Administration (SAMHSA). Protracted Withdrawal. Substance Abuse Treatment Advisory. 2010;9(1). SMA10-4554. SAMHSA Library.
8. National Institute for Health and Care Excellence. Depression in adults: treatment and management (NG222). NICE; 2022. NICE NG222.
9. Framer A. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. Ther Adv Psychopharmacol. 2021;11:2045125321991274. PMID: 33796265.